Literature DB >> 1394824

Factors affecting the outcome of patients with advanced urothelial cancer following chemotherapy with methotrexate, vinblastine, adriamycin, and cisplatin.

M Igawa1, T Ohkuchi, M Ueda, T Usui.   

Abstract

Attempts were made to identify factors related to the response of patients treated with intravenous methotrexate, vinblastine, Adriamycin, and cisplatin (M-VAC). The subjects consisted of 54 patients with advanced urothelial cancer whose histological type was transitional-cell carcinoma. The effects of various factors on the response were studied using univariate analysis and a multiple logistic regression model. The following factors were included in the analyses: (1) age, (2) sex, (3) performance status (PS), (4) primary site, (5) histological grade, (6) T category, (7) N category, (8) M category, (9) tumor status, and (10) dose of drugs. In all, 9 patients achieved a complete response and 23 showed a partial response, for an overall response rate of 59% (95% confidence limits, 46%-72%). Univariate analysis revealed that the PS, M category, and dose of drugs were related to the response, and there was a significant correlation among these three factors. In the multiple logistic regression model, the absolute value of t was high for the M category. The presence of distant metastases is an important factor in predicting poor efficacy for the present regimen. The management of metastatic disease will be the subject of further study in the treatment of advanced urothelial cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394824     DOI: 10.1007/bf00686948

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  6 in total

1.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.

Authors:  C N Sternberg; A Yagoda; H I Scher; R C Watson; H W Herr; M J Morse; P C Sogani; E D Vaughan; N Bander; L R Weiselberg
Journal:  J Urol       Date:  1988-03       Impact factor: 7.450

2.  Multivariate analysis of prognostic factors in metastatic breast cancer.

Authors:  G N Hortobagyi; T L Smith; S S Legha; K D Swenerton; E A Gehan; H Y Yap; A U Buzdar; G R Blumenschein
Journal:  J Clin Oncol       Date:  1983-12       Impact factor: 44.544

3.  Phase II trial of sequentially administered cisplatin, cyclophosphamide and doxorubicin for urothelial tract tumors.

Authors:  S Schwartz; A Yagoda; R B Natale; R C Watson; W F Whitmore; M Lesser
Journal:  J Urol       Date:  1983-10       Impact factor: 7.450

4.  Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.

Authors:  C N Sternberg; A Yagoda; H I Scher; R C Watson; T Ahmed; L R Weiselberg; N Geller; P S Hollander; H W Herr; P C Sogani
Journal:  J Urol       Date:  1985-03       Impact factor: 7.450

5.  Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer.

Authors:  M Igawa; T Ohkuchi; T Ueki; M Ueda; K Okada; T Usui
Journal:  J Urol       Date:  1990-09       Impact factor: 7.450

6.  Cyclophosphamide, doxorubicin, and cisplatin (CAP) in the treatment of urothelial malignancy: a pilot study of the Southeastern Cancer Study Group.

Authors:  M B Troner; G P Hemstreet
Journal:  Cancer Treat Rep       Date:  1981 Jan-Feb
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.